Next Article in Journal
Role of Oxidative Stress in Diabetic Cardiomyopathy
Next Article in Special Issue
Computation-Assisted Identification of Bioactive Compounds in Botanical Extracts: A Case Study of Anti-Inflammatory Natural Products from Hops
Previous Article in Journal
HO-1 Upregulation by Kaempferol via ROS-Dependent Nrf2-ARE Cascade Attenuates Lipopolysaccharide-Mediated Intercellular Cell Adhesion Molecule-1 Expression in Human Pulmonary Alveolar Epithelial Cells
Previous Article in Special Issue
Meso-Dihydroguaiaretic Acid Ameliorates Acute Respiratory Distress Syndrome through Inhibiting Neutrophilic Inflammation and Scavenging Free Radical
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antioxidants
Volume 11
Issue 4
10.3390/antiox11040783
antioxidants-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Effect of Dietary Phenolic Compounds on Incidence of Cardiovascular Disease in the SUN Project; 10 Years of Follow-Up

by
Zenaida Vázquez-Ruiz
1,2,
Estefanía Toledo
1,2,
Facundo Vitelli-Storelli
3,
Leticia Goni
1,2,
Víctor de la O
1,2,
Maira Bes-Rastrollo
1,2 and
Miguel Ángel Martínez-González
1,2,4,*
1
Department of Preventive Medicine and Public Health, Instituto de Investigación Sanitaria de Navarra (IdiSNA), University of Navarra, 31008 Pamplona, Spain
2
Biomedical Research Network Centre for Pathophysiology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, 28029 Madrid, Spain
3
Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Instituto de Biomedicina (IBIOMED), Universidad de León, 24071 León, Spain
4
Department of Nutrition, Harvard T. H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA
*
Author to whom correspondence should be addressed.
Antioxidants 2022, 11(4), 783; https://doi.org/10.3390/antiox11040783
Submission received: 30 March 2022 / Revised: 12 April 2022 / Accepted: 13 April 2022 / Published: 14 April 2022
(This article belongs to the Special Issue Antioxidant Activity of “Polyphenolic-Food” and Human Health – 2nd Edition)
Browse Figures
Review Reports Versions Notes

Abstract

:
The health benefits of plant-based diets have been reported. Plant-based diets found in Spain and other Mediterranean countries differ from typical diets in other countries. In the Mediterranean diet, a high intake of phenolic compounds through olives, olive oil, and red wine may play an important role in cardiovascular prevention. Prospective studies carried out in Mediterranean countries may provide interesting insights. A relatively young Mediterranean cohort of 16,147 Spanish participants free of cardiovascular disease (CVD) was followed (61% women, mean (SD) age 37(12) years at baseline) for a median of 12.2 years. Dietary intake was repeatedly assessed using a 136-item validated food frequency questionnaire, and (poly)phenol intake was obtained using the Phenol-Explorer database. Participants were classified as incident cases of CVD if a medical diagnosis of myocardial infarction, stroke, or cardiovascular death was medically confirmed. Time-dependent Cox regression models were used to assess the relationship between (poly)phenol intake and the incidence of major CVD. A suboptimal intake of phenolic compounds was independently associated with a higher risk of CVD, multivariable-adjusted hazard ratio for the lowest versus top 4 quintiles: 1.85 (95% CI: 1.09–3.16). A moderate-to-high dietary intake of phenolic compounds, especially flavonoids, is likely to reduce CVD incidence in the context of a Mediterranean dietary pattern.

1. Introduction

Cardiovascular disease (CVD) is the largest cause of mortality in Western countries, and 17.9 million people globally died in 2019 from CVDs (32% of all-cause global mortality), mostly from coronary heart disease and stroke [1]. According to the World Health Organization, most CVDs can be avoided by addressing risk factors such as obesity, hypertension, dyslipidemia, diabetes, tobacco use, sedentary lifestyle, alcohol abuse, and high consumption of ultra-processed foods [2,3]. Nutritional compounds present in foods have a key influence on human health, even though the relationship between different dietary compounds and health is complex and intertwined with each other, as well as with other health determinants. Available evidence supports that some dietary strategies, such as the traditional Mediterranean dietary pattern, rich in extra-virgin olive oil, fruit, and vegetables may delay or prevent chronic illness, such as CVD or type 2 diabetes (T2D) [4,5,6,7,8]. The high concentration of bioactive compounds, such as (poly)phenols, present in this dietary pattern may exert antioxidant, anti-inflammatory, and antithrombotic effects that contribute to the delay of CVD onset and progression [9,10,11].
Phenolic compounds are secondary plant metabolites contained in a large diversity of vegetables, fruits, nuts, seeds, cereals, oils, coffee, chocolate, and spices, and their structure has in common at least one aromatic ring attached to a hydroxyl group. These compounds show a wide structural diversity, and they can be grouped into five classes: flavonoids, phenolic acids, stilbenes, lignans, and other (poly)phenols [12]. In plants, phenolic compounds promote plant survival by acting as pollinators, protecting against ultraviolet radiation, and scavenging reactive oxygen species (ROS). Some of these protective features apparently translate to human health as well, promoting longevity by lowering the incidence of chronic diseases. The absorption, transport, bioavailability, and bioactivity of (poly)phenols after food intake vary depending on the type of compound. Some of them are absorbed in the stomach, while others, such as catechins, flavanols, and flavones, pass into the circulatory system through the small intestine. In general, the absorption of phenolic compounds is related to the release of aglycone, which is partly the result of microbial activity and digestive enzymes. During the aglycone route along the human body up to urine excretion, phenolic compound interactions may modulate potential risk factors of chronic disease by promoting cardioprotective effects and improving insulin sensitivity [13,14].
In addition, phenolic compounds may have antioxidant effects by counteracting senescence and protecting the mitochondrial function of vascular and endothelial smooth muscle cells by modulating signal transduction [15]. An increased expression of ROS-generating molecules and/or a decrease in antioxidant enzyme expression, such as catalase, superoxide dismutase, and glutathione peroxidase, promote the accumulation of ROS, causing damage to DNA, lipids, and proteins generating oxidative stress in the organism [16]. This accumulation of damaged molecules and dysregulation of mitochondrial function results in a state of oxidative stress, involving lipid peroxidation, which is associated with an increased incidence of age-related diseases, such as CVD, cancer, and other chronic diseases [17].
In this regard, oxidative modifications of low-density lipoproteins to oxidized LDL are one of the first events in the progression of atherosclerosis, and (poly)phenols have been shown to fight this process, exerting antioxidant activity through endogenous and exogenous mechanisms [18]. Flavonoids (flavonols, flavanols, flavanones, and flavones) and stilbenes are oxidized by free radicals, giving rise to more stable and less reactive compounds. Moreover, flavanones, anthocyanins, and phenolic acids have been shown to have antioxidant activity by enhancing cellular antioxidant defenses through activation of antioxidant and cytoprotective enzyme transcription factors [19,20]. Another pathway by which (poly)phenols exhibit their antioxidant function is modification of signal transduction that can promote up-regulation of antioxidant genes and induction of endogenous antioxidant enzymes, such as glutathione peroxidase, superoxide dismutase, catalase, or glutathione reductase [18].
Many sources of phenolic compounds, such as red wine, extra-virgin olive oil, and green tea, have the potential to improve vascular health by promoting the production of vasoprotective factors and by enhancing vascular smooth muscle function. Endothelial dysfunction is greatly caused by reduced nitric oxide (NO) availability because of increased oxidative stress, free radical generation, and other stress factors; (poly)phenols can improve NO release from endothelial cells, leading to activation of cyclic guanosine monophosphate in vascular smooth muscle cells and exerting a vessel relaxation, antioxidant, anti-inflammatory, and antithrombotic effect [18,21]. The antioxidant effect of (poly)phenols probably reflects reduced oxidative stress and may prevent vasoconstriction and pro-inflammatory responses.
In contrast, some negative effects have been reported for certain phenolic compound intake, e.g., iron chelation. The inhibiting effect of (poly)phenols on iron absorption has been shown in black tea and herb teas and may lead to poor iron status [22].
The purported benefits of (poly)phenol intake (PPI) are best evaluated in prospective cohorts with long follow-up, good control for confounding, a high retention rate, and a high variability in PPI. In the traditional Mediterranean diet, a high intake of phenolic compounds through olives, extra-virgin olive oil, and red wine may play an important role in cardiovascular prevention. These sources of phenolic compounds are likely to be different from those found in non-Mediterranean countries. However, when average intake is high, as is expected to happen with the Mediterranean diet, wide intake variability can be found. The aim of this study was to evaluate prospectively in a Mediterranean population the association of total PPI, and (poly)phenol subclasses with the incidence of CVD in the Seguimiento Universidad de Navarra (SUN) cohort of university graduates.

2. Materials and Methods

2.1. Study Population

The SUN project is a prospective, multipurpose, and dynamic cohort of Spanish university graduates whose recruitment started in December 1999 and nowadays involves almost 23,000 Spanish college graduates. A more detailed description of the cohort design and methodology is available elsewhere [23]. Briefly, self-reported questionnaires received through postal mail or the web collected information at baseline about sociodemographic characteristics, health status, family history of diseases, and lifestyle of the participants. Every two years, information about lifestyle factors, especially eating habits and health outcomes, was updated.
For these analyses, participants who were recently recruited and had less than 2 years and 9 months of follow-up (n = 341) were excluded, as well as those whose total energy intake was outside of predefined limits (<500 or >3500 kcal/d in females, or <800 or >4000 kcal/d in males) [24] (n = 2142) and who did not adequately answer the food frequency questionnaire (FFQ) (more than 15 items missing) (n = 2552). Additionally, participants with prevalent CVD (n = 247) and lost follow-up (n = 1465) were excluded. In total, 16,147 participants were included in this analysis, with a mean follow-up time of 11.5 years (SD = 4.5) and a retention rate of 91.7% (Figure 1).

2.2. Assessment of Dietary Intake and (Poly)Phenol Intake

A validated semi-quantitative FFQ with 136 food records was used to assess previous dietary intake and after a 10-year follow-up [25,26]. Each food was grouped into nine categories of consumption (never or seldom; 1–3 times/month; once a week; 2–4 times/week; 5–6 times/week; once a day; 2–3 times/day; 4–6 times/day and >6 times/day). To compute daily energy and nutrient intakes, Spanish food composition tables were used, and standard serving sizes were multiplied by the frequency of consumption of each food [27,28].
(Poly)phenol content provided by foods was obtained from the Phenol-Explorer database 3.6 version (www.phenol-explorer.eu, accessed on 1 October 2021) whose methodology is published elsewhere [29,30]. Foods with no or only traces of (poly)phenols were excluded. For the recipes and processed foods, (poly)phenol content was computed according to their ingredients. The most common extraction method for estimating PPI was high-performance liquid chromatography (HPLC), which quantifies (poly)phenol glycosides, phenolic acid esters together with aglycones and free phenolic acids concurrently, and normal-phase HPLC for proanthocyanidins. In the case of lignans, and phenolic acids in certain foods, such as cereals, olives, and beans, data corresponding to HPLC after hydrolysis were used to calculate the aglycone. This analytical method uses acid or alkaline hydrolysis to release certain compounds, such as insoluble phenolic acids esterified to the cell wall of cereals, which cannot be solubilized without hydrolysis. When food items of the FFQ included more than one food, a weighted average was used according to the average dietary intake in the adult Spanish population [31]. Finally, the individual PPI of each food was obtained by multiplying the content of each (poly)phenol by the daily consumption of each food. The total PPI was determined (milligrams per day) as the sum of all the individual PPIs of every food record reported by the FFQ. A ratio of the total or individual (poly)phenols contributed by the specific food or food group to the total (poly)phenol intake of all foods was calculated.

2.3. Outcome Assessment

The incidence of CVD was the endpoint of this study, and it included myocardial infarction diagnosed using universal criteria, non-fatal stroke defined as a sudden onset focal-neurological deficit with a vascular mechanism that lasted more than 24 h, and CVD death [32]. Clinical records or information were requested to participants or their families to confirm the event when CVD was self-reported in any of the biennial follow-up questionnaires. All CVD case information was revised and confirmed by an expert medical panel that was blind to participant diet and lifestyle exposure and classified according to the International Classification of Diseases (ICD 10). CVD deaths were confirmed through death certificates and the database of the Spanish National Statistic Institute.

2.4. Assessment of Covariates

At baseline, participants provided information about possible confounders, including socio-demographic characteristics (sex, age, level of education, and marital status), validated anthropometric measures [33] (weight and height), and health-related behavior such as alcohol intake, smoking status, leisure-time watching TV, or physical activity (METs-h/week) [34]. Family and personal medical history (hypertension, hypercholesterolemia, diabetes, cancer, or CVD, among others) was also reported and ascertained at baseline. Some validation studies in the SUN cohort assessed the reliability of self-reported medical data [35,36].

2.5. Statistical Analysis

PPI values were adjusted for total energy according to the residual method proposed by Willett [24] and were categorized into sex-specific quintiles. Descriptive statistics were used to analyze participants’ characteristics at baseline adjusted for age and sex using the inverse probability weighting method, using proportions or means (and standard deviations, SD) according to quintiles of PPI. The main sources of total PPI, and (poly)phenol classes and subclasses intake were calculated, as well as the contribution of each food item to total (poly)phenol and subclasses intake.
Crude and multivariable Cox regression models were used to analyze CVD risk and PPI using age as the underlying time variable, with quintiles of total energy-adjusted PPI intake or PPI classes as the independent variable. Time at entry was defined as the date of completion of the first questionnaire, and time at exit as the date of the cardiovascular event or date at which participants filled out their last follow-up questionnaire or the date of death due to a non-CVD-related cause for non-cases. Multivariable adjusted model 1 was stratified by age (five-year periods), recruitment period, marital status, and years of university education and adjusted for energy intake (kcal/day), smoking status (never smoker, current smoker or former smoker), lifetime tobacco exposure (packs-years), body mass index (BMI) (kg/m2) and the quadratic term, prevalent dyslipidemia, hypertension, and diabetes, family history of CVD, physical activity (METs-h/week, continuous), TV watching (hours/day, continuous), use of cardiovascular drugs (yes/no), health consciousness (number of medical check-ups, quintiles), energy-adjusted alcohol (g/day) intake, and energy-adjusted (g/day) sodium intake.
Hazard ratios (HRs) were calculated with their 95% confidence interval (CIs), including age as the underlying time variable and always considering the lowest quintile as the reference category. Repeated measurements were performed to evaluate dietary intake variation effect on those participants who completed the FFQ after 10-year follow-up (Q10 questionnaire) using cumulative average for dietary variables to reduce the effect of dietary intake variations at 10 years of follow-up, and the analysis was stratified and adjusted for the same confounders as in model 1. HRs in model 1 and repeated measurements were calculated excluding participants with 40 years of age or less to evaluate if the effect was restricted to subjects older than 40 years. The date on which they turn 40 years old, if applied, was used as entry in the regression model adjusted for the same confounders as the initial sample. In addition, HRs were estimated to assess the effect of a low (or suboptimal) PPI (first quintile of total PPI) versus a moderate-high intake (quintiles 2 to 5 of PPI). All analyses were repeated for each (poly)phenol subclass.
Multivariable-adjusted Nelson–Aalen curves were employed to describe the incidence of CVD across quintiles (Q1 vs. Q2–Q5) of total PPI to assess absolute risk along the follow-up period. To adjust these curves, inverse probability weighting methods were applied. Sensitivity analyses were performed by rerunning the same analysis, not excluding participants with incomplete FFQ at baseline, and the results remained similar. The analyses were performed with the Stata statistical software package version 16 (College Station, TX, USA; Stata Corp LLC). All p-values presented are two-tailed, and the statistical significance was set at 0.05.

3. Results

The main baseline characteristics of the 16,147 participants included in the analyses according to the energy-adjusted quintiles of the baseline total PPI are shown in Table 1. The mean age of the participants was 37 years (SD = 12), and the median BMI was 23.5 kg/m2 (SD = 3.5).
Participants in the first quintile of total PPI showed the highest total energy intake and fat intake, while carbohydrate, protein, fiber, and alcohol intakes were the lowest for the lowest quintile. This first quintile also exhibited the lowest average level of leisure-time physical activity (MET-h/week) at baseline. Participants in the lowest quintile of PPI showed a higher use of cardiovascular drugs, hypertension, and diabetes at baseline but also the highest proportion of never smokers. Flavonoid intake was the (poly)phenol class that increased most across quintiles of total PPI. Adherence to the Mediterranean diet increased progressively from the first quintile to the fifth.
The energy-adjusted mean ± SD of total PPI was 779.7 ± 371.6 mg/day, of which 55.5% were flavonoids (432.8 ± 271.6 mg/day), 38.8% phenolic acids (302.9 ± 151.9 mg/day), 5% other (poly)phenols (40.5 ± 33.1), 0.28% lignans (2.2 ± 1.0 mg/day), and 0.15% stilbenes (1.2 ± 2.6 mg/day) (Table 2). The class that contributed the most to total PPI was flavonoids, followed by phenols acids, but the highest subclass contributor to total PPI was a phenolic acids subclass, hydroxycinnamic acids (266.3 ± 140.1 mg/day, 34.15%), followed by a flavonoid subclass, proanthocyanidins (221.3 ± 198.2 mg/day, 28.38%).
Regarding (poly)phenol subclasses, the main contributor to flavonoids was proanthocyanidins (221.3 ± 198.2 mg/day) and the principal food source of flavanoids was chocolate (44.4%), apple (21%), cherries (11.1%), and strawberries (5.3%). The group of flavanones (74.6 ± 75.8 mg/day) was the second subclass contributor to flavonoids and was basically provided by oranges (33.7%), natural orange juice (27.5%), and fruit juices from concentrates (18.7%). Among phenol acids, hydroxycinnamic acids had the highest intake (66.3 ± 140.1 mg/day) with coffee (31.8%) and decaffeinated coffee (12.7%) as the main food sources, and hydroxybenzoic acids showed lower intakes (31.6 ± 24.8 mg/day) largely provided by nuts (34%), olives (16.41%), and strawberries (13%). Olives were the main food source for hydroxyphenylacetic acids (4.44 ± 6.9 mg/day) and hydroxyphenylpropanoic acids (0.6 ± 1 mg/day). Lignan intake (2.2 ± 1.1 mg/day) was mostly provided by carrot and pumpkin (13.3%) and olive oil (11.2%), while the principal supply for stilbenes (1.2 ± 2.6 mg/day) was red wine (88.6%). Tyrosol intake (27.2 ± 29.9 mg/day) was the most abundant element within the subclass of “other (poly)phenols” with olives (66.1%) and olive oil (28.9%) as principal food contributors.
Among 185,652 person-years of follow-up, a total of 123 medically-confirmed new onset cases of CVD were observed (median follow-up 11.5 years). A low intake vs. medium–high total PPI analysis showed a significantly higher risk of CVD incidence (adjusted multivariable model 1 HRQ1 vs. Q2–Q5 2.12; 95% CI 1.27–3.57; p < 0.001) (Table 3). When analyses were restricted to participants older than 40 years, lower HRs were observed, but results did not remain significant. Once repeated measurements were applied, an increased risk remained significant (adjusted multivariable model 1 HRQ1 vs. Q2–Q5 1.85; 95% CI 1.09–3.16; p < 0.05).
When low versus medium–high flavonoid intake was analyzed, the results showed a significantly higher risk in quintile 1 of flavonoid intake in the crude model. (HRQ1 vs. Q2–Q5 1.86; 95% CI 1.20–2.87; p < 0.001), multivariable model 1 (HRQ1 vs. Q2–Q5 1.73; 95% CI 1.03–2.90; p < 0.05) and using repeated measurements (HRQ1 vs. Q2–Q5 1.88; 95% CI 1.11–3.17; p < 0.05). Restricting the analyses to participants older than 40 years, the results remained significant, and HRs were higher in multivariable model 1 (HRQ1 vs. Q2–Q5 2.27; 95% CI 1.33–3.88; p < 0.001) and in repeated measurement analyses (HRQ1 vs. Q2–Q5 1.97; 95% CI 1.19–3.27; p < 0.001).
For lignan intake, significant results were only observed in a low intake when analyses were restricted to participants older than 40 years in multivariable model 1 (HRQ1 vs. Q2–Q5 1.83; 95% CI 1.03–3.25; p < 0.05), but it was the only class of phenolic compounds that showed a significant linear trend (p < 0.05) across quintiles in all regression models conducted. Regarding phenol acids, significant results were only observed for low intake (HRQ1 vs. Q2–Q5 1.97; 95% CI 1.12–3.45; p < 0.05) when analyses were conducted on participants older than 40 years in multivariable model 1.
Cumulative HR for CVD development over time across quintiles of total PPI was graphically represented using Nelson–Aalen curves with adjustment for the same variables as model 1 but using inverse probability weighting and according to a low total PPI (first quintile, Q1) versus medium–high total PPI (Q2–Q5), which showed a higher absolute risk of CVD in the lowest quintile of total PI, with diverging curves starting after 2 year follow-up (Figure 2). Sensitivity analyses were performed repeating the same analysis without excluding the 2552 participants with incomplete questionnaires (more than 15 items missing) at baseline), and the results remained similar.

4. Discussion

These results suggest that a suboptimal intake (432.1 mg/day or less) of total (poly)phenols and a low flavonoid intake (190.7 mg/day or less) are associated with increased CVD risk. These findings are in line with previous analyses of PPI in a smaller subsample of the SUN cohort, with a shorter follow-up and in which repeated measurements of PPI during follow-up were not used [38]. It can now be confirmed that the cardioprotective effect persists when repeated measurements at 10 years of follow-up are performed. In addition, the natural history of the occurrence of CVD related to phenolic compounds could be plotted, showing changes in absolute risks over the follow-up period.
Evidence from randomized controlled trials designed to assess primary prevention of cardiovascular disease in Mediterranean populations described the role of phenolic compounds in cardiovascular health and reported an inverse relationship between dietary intake of phenolic compounds and the risk of CVD, consistent with the results shown in this study [39,40]. Findings also revealed a meaningful role of flavonoid subclasses in reducing the risk of CVD. They could be explained by proanthocyanidins and flavonols intake, which are the main flavonoid compounds contributing to the total PPI. Some studies supported a beneficial effect of proanthocyanidin-rich foods, but they also mentioned that bioavailability of the polymerized proanthocyanidins is very limited, and the biological active compounds should be investigated in the monomeric forms of the proanthocyanidins, the catechins, and in the set of metabolic compounds generated by degradation of the proanthocyanidins in the intestine, which can be interrelated with gut microbiota activity [41,42,43,44].
A dose-response meta-analysis [45] studied the association between dietary intake of total subclasses and individual flavonoids and risk of CVD. It provided evidence about the potential cardiovascular benefits of a flavonol-rich diet. Moreover, a systematic review and meta-analysis of prospective cohort studies found that flavonol intake was inversely associated with CVD risk in either US or European populations [46]. In addition, the results of the dose-response analysis indicated that an average increase of 10 mg/day of flavonol intake was associated with a 5% lower risk of CVD. Possible mechanisms by which flavonols may decrease the risk of CVD probably involve more than one effect. In brief, there is solid evidence that, in vitro, quercetin, and related flavonols exert endothelium vasodilator effects, protective effects on endothelial function against oxidative stress, platelet antiaggregant effects, inhibition of low-density lipoprotein oxidation, and reduction of adhesion molecules and other inflammatory markers [47,48]. Moreover, evidence suggests that quercetin may be a key compound preventing the most common forms of CVD and contributing to the protective effects provided by fruits and vegetables, which is consistent with food sources of flavonols reported here in the SUN cohort [49,50].
Regarding lignans, a significantly higher risk of CVD was found in the lowest intake quintile and a significant inverse linear trend across quintiles of intake in participants older than 40 years. Previous studies found a lower risk of total CVD associated with a high long-term intake of lignans, although the effect may be explained by a possible synergy with fiber intake [51]. Lignans in the present study were mainly supplied by carrot and pumpkin (13.3%), which are vegetables with high concentrations of beta-carotenes. In this context, a review indicated that beta-carotene and its vitamin A derivatives may stimulate lipid catabolism in several tissues and may play a role in immune cells, which are related to the physiopathology of CVD onset [52,53]. Olive oil was the second source of lignans (11.2%), and its protective role against CVD has been widely studied both in Mediterranean and non-Mediterranean countries [7,54,55,56,57].
Phenolic acid intake, of which coffee hydroxycinnamic acids were the main source in this study, showed a significant increase of CVD risk in the lowest quintile of intake in those over 40 years of age, and some evidence explained the mechanisms of endothelial protection by hydroxycinnamic acids, suggesting a potential role in prevention of thrombus formation or atherosclerotic lesion development [58]. Recent data from large observational studies have shown possible associations between phenolic acid intake and improvements in blood pressure and metabolic syndrome, although evidence from randomized clinical trials presents some inconsistencies due to individual variation in the diversity of the microbiota and the influence it exerts on the effective use of phenolic acids in the human body [59].
Randomized controlled trials have evaluated the role of isolated phenolic compounds in cardiovascular prevention, taken as a complement and eliminating the possible synergies that could be obtained by the contribution of nutrients, vitamins, and minerals from fruits and vegetables that are naturally present and that can be a bias when evaluating the cardioprotective effect. In some of them, improvements in endothelial function, metabolic syndrome components, lipid metabolism parameters, and antioxidant and anti-inflammatory improvement were shown, but in contrast, another randomized controlled trial with a daily intake of 25 mg pure (-)-epicatechin for 2 weeks did not show cardiometabolic risk factor improvements outside of its food matrix [60,61,62,63]. Therefore, it appears that the action of polyphenols on human metabolism may change when ingested in isolation or in combination with the dietary components of food.
Some limitations may be observed in the present study. One of them can be related to the estimation of PPI, even though the most updated and comprehensive database available was used (Phenol-explorer version 3.6), not all foods from FFQ are included in the database (e.g., honey), FFQ does not cover all (poly)phenol-rich foods (e.g., spices or herbs) and also does not distinguish food details that can affect the (poly)phenol content (types of tea, coffee or cocoa percentage of different varieties of chocolate) nonetheless some validation studies have shown that FFQ are soundly valid for estimating (poly)phenol intake [64]. Furthermore, bioavailability after ingestion was not considered and may vary among individuals. In addition, phenolic intake can be affected by external conditions that may affect the food (poly)phenol content, such as ripeness, processing, and storage, and variety can affect the food (poly)phenol richness [12]. Fortunately for our participants, the number of events in the SUN project was relatively low, as expected in a relatively young and healthy Mediterranean cohort. Nevertheless, this fact may have limited our statistical power for assessing these associations, and the lack of significance in HR of quintiles may be due to the low number of events in this Mediterranean cohort.
This study also has several strengths, including its prospective design, comprehensive, and validated data about potential confounders, ascertainment of events by a medical panel, and a high retention rate of the cohort (92%). Additionally, dietary measurement errors were reduced by considering changes in diet at the 10-year follow-up, which enabled us to calculate the cumulative average of nutrient exposure for a better representativeness of dietary intake over time. Moreover, this study was conducted in a Mediterranean country, which may help to adequately capture the effect of high (poly)phenol content foods, such as olive oil or red wine traditionally present in the Mediterranean diet and with a high observed consumption in this population.

5. Conclusions

These findings support the avoidance of suboptimal PPI and the promotion of (poly)phenol-rich diets, especially flavonoid-rich dietary patterns, to reduce the risk of CVD. Flavonoids were found most abundantly in fruits, vegetables, cocoa, and wine in our cohort. Future research, especially randomized controlled trials, should be led to control phenolics intake confounding by culinary preparations that strongly influence the bioavailability of these compounds. Further research is needed to characterize interactions with gut microbiota and with systemic tissues.

Author Contributions

Conceptualization, M.Á.M.-G. and E.T.; methodology, M.Á.M.-G. and E.T. validation and formal analysis, Z.V.-R., E.T. and M.Á.M.-G.; resources, E.T. and M.Á.M.-G.; data curation, Z.V.-R., F.V.-S., E.T., L.G., V.d.l.O., M.B.-R. and M.Á.M.-G.; writing—original draft preparation, Z.V.-R. and M.Á.M.-G.; writing—review and editing, Z.V.-R., F.V.-S., E.T., L.G., V.d.l.O., M.Á.M.-G. and M.B.-R.; supervision, M.Á.M.-G. and E.T.; project administration, M.Á.M.-G. and M.B.-R.; funding acquisition, M.Á.M.-G. and M.B.-R. All authors have read and agreed to the published version of the manuscript.

Funding

The project SUN has received funding from the Spanish Government—Instituto de Salud Carlos III, the European Regional Development Fund (FEDER) (RD 06/0045, CIBER-OBN, Grants PI10/02658, PI10/02293, PI13/00615, PI14/01668, PI14/01798, PI14/01764, PI17/01795, PI20/00564 and G03/140), the Government of Navarra (27/2011, 45/2011, 122/2014), the National Plan on Drugs (2020/021), and the University of Navarra.

Institutional Review Board Statement

The SUN cohort was conducted according to the guidelines of the Declaration of Helsinki and is registered at clinicaltrials.gov (accessed on 22 March 2021) as NCT02669602. The present study was approved by the Institutional Review Board of University of Navarra (protocol code 010830).

Informed Consent Statement

Potential candidates were informed of their right to refuse to participate or to withdraw their consent to participate in the SUN project at any time without reprisal, according to the principles of the Declaration of Helsinki. Voluntary completion of the baseline questionnaire was considered to imply informed consent to participate in the study.

Data Availability Statement

All of the data is contained within the article.

Acknowledgments

We thank all participants in the SUN cohort for their long-standing and enthusiastic collaboration and our advisors from Harvard TH Chan School of Public Health, Walter Willett, Alberto Ascherio, Frank B. Hu, and Meir J. Stampfer, who helped us to design the SUN Project, the PREDIMED study, and the PREDIMED-PLUS on-going trial. We thank other members of the SUN Group: Aguilera-Buenosvinos I., Alonso A., Álvarez-Álvarez I., Balaguer A., Barbería-Latasa M., Barrio-López M.T., Basterra-Gortari F.J., Battezzati A., Bazal P., Benito S., Bertoli S., Beunza J.J., Buil-Cosiales P., Carlos S., de Irala J., de la Fuente-Arrillaga C., de la Rosa P.A., Delgado-Rodríguez M., Díaz-Gutiérrez J., Díez Espino J., Domínguez L., Donat-Vargas C., Donazar M., Eguaras S., Fernández-Lázaro C.I., Fernández-Montero A., Fresán U., Galbete C., García-Arellano A., Gardeazábal I., Gea A., Gutiérrez-Bedmar M., Gomes-Domingos A.L., Gómez-Donoso C., Gómez-Gracia E., Goñi E., Guillén F., Hernández-Hernández A., Hershey M.S., Hidalgo-Santamaría M., Hu E., Lahortiga F., Leone A., Llavero M., Llorca J., López del Burgo C., Marí A., Martí A., Martín-Calvo N., Martín-Moreno J.M., Martínez J.A., Martínez-González M.A., Mendonça R., Menéndez C., Molendijk M., Molero P., Muñoz M., Navarro A.M., Pano O., Pérez de Ciriza P., Pérez-Cornago A., Pérez de Rojas J., Pimenta A.M., Ramallal R., Razquin C., Rico-Campà A., Romanos-Nanclares A., Ruiz L., Ruiz-Canela M., San Julián B., Sánchez D., Sánchez-Bayona R., Sánchez-Tainta A., Sánchez-Villegas A., Santiago S., Sayón-Orea C. and Zazpe I.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in study design, data collection, analysis and interpretation, decision to publish, or preparation of the manuscript.

References

  1. World Health Organization. Cardiovascular Diseases. Available online: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1 (accessed on 25 March 2022).
  2. Srour, B.; Fezeu, L.K.; Kesse-Guyot, E.; Allès, B.; Méjean, C.; Andrianasolo, R.M.; Chazelas, E.; Deschasaux, M.; Hercberg, S.; Galan, P.; et al. Ultra-processed food intake and risk of cardiovascular disease: Prospective cohort study (NutriNet-Santé). BMJ 2019, 365, l1451. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. De Deus Mendonça, R.; Pimenta, A.M.; Gea, A.; De La Fuente-Arrillaga, C.; Martinez-Gonzalez, M.A.; Lopes, A.C.S.; Bes-Rastrollo, M. Ultraprocessed food consumption and risk of overweight and obesity: The University of Navarra Follow-Up (SUN) cohort study. Am. J. Clin. Nutr. 2016, 104, 1433–1440. [Google Scholar] [CrossRef] [PubMed]
  4. Tosti, V.; Bertozzi, B.; Fontana, L. Health Benefits of the Mediterranean Diet: Metabolic and Molecular Mechanisms. J. Gerontol. Ser. A 2018, 73, 318–326. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Mozaffarian, D.; Ludwig, D.S. Dietary Guidelines in the 21st Century—A Time for Food. JAMA 2010, 304, 681–682. [Google Scholar] [CrossRef]
  6. Trichopoulou, A.; Martínez-González, M.A.; Tong, T.Y.; Forouhi, N.G.; Khandelwal, S.; Prabhakaran, D.; Mozaffarian, D.; de Lorgeril, M. Definitions and potential health benefits of the Mediterranean diet: Views from experts around the world. BMC Med. 2014, 12, 112. [Google Scholar] [CrossRef] [Green Version]
  7. Estruch, R.; Ros, E.; Salas-Salvadó, J.; Covas, M.-I.; Corella, D.; Arós, F.; Gómez-Gracia, E.; Ruiz-Gutiérrez, V.; Fiol, M.; Lapetra, J.; et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N. Engl. J. Med. 2018, 378, e34. [Google Scholar] [CrossRef]
  8. Guasch-Ferré, M.; Merino, J.; Sun, Q.; Fitó, M.; Salas-Salvadó, J. Dietary Polyphenols, Mediterranean Diet, Prediabetes, and Type 2 Diabetes: A Narrative Review of the Evidence. Oxid. Med. Cell. Longev. 2017, 2017, 6723931. [Google Scholar] [CrossRef]
  9. George, E.S.; Marshall, S.; Mayr, H.L.; Trakman, G.L.; Tatucu-Babet, O.A.; Lassemillante, A.-C.M.; Bramley, A.; Reddy, A.J.; Forsyth, A.; Tierney, A.C.; et al. The effect of high-polyphenol extra virgin olive oil on cardiovascular risk factors: A systematic review and meta-analysis. Crit. Rev. Food Sci. Nutr. 2019, 59, 2772–2795. [Google Scholar] [CrossRef]
  10. Potì, F.; Santi, D.; Spaggiari, G.; Zimetti, F.; Zanotti, I. Polyphenol Health Effects on Cardiovascular and Neurodegenerative Disorders: A Review and Meta-Analysis. Int. J. Mol. Sci. 2019, 20, 351. [Google Scholar] [CrossRef] [Green Version]
  11. Rienks, J.; Barbaresko, J.; Nöthlings, U. Association of Polyphenol Biomarkers with Cardiovascular Disease and Mortality Risk: A Systematic Review and Meta-Analysis of Observational Studies. Nutrients 2017, 9, 415. [Google Scholar] [CrossRef] [Green Version]
  12. Manach, C.; Scalbert, A.; Morand, C.; Rémésy, C.; Jiménez, L. Polyphenols: Food sources and bioavailability. Am. J. Clin. Nutr. 2004, 79, 727–747. [Google Scholar] [CrossRef] [Green Version]
  13. Teng, H.; Chen, L. Polyphenols and bioavailability: An update. Crit. Rev. Food Sci. Nutr. 2019, 59, 2040–2051. [Google Scholar] [CrossRef]
  14. Di Lorenzo, C.; Colombo, F.; Biella, S.; Stockley, C.; Restani, P. Polyphenols and Human Health: The Role of Bioavailability. Nutrients 2021, 13, 273. [Google Scholar] [CrossRef]
  15. Serino, A.; Salazar, G. Protective Role of Polyphenols against Vascular Inflammation, Aging and Cardiovascular Disease. Nutrients 2018, 11, 53. [Google Scholar] [CrossRef] [Green Version]
  16. Forni, C.; Facchiano, F.; Bartoli, M.; Pieretti, S.; Facchiano, A.; D’Arcangelo, D.; Norelli, S.; Valle, G.; Nisini, R.; Beninati, S.; et al. Beneficial Role of Phytochemicals on Oxidative Stress and Age-Related Diseases. BioMed Res. Int. 2019, 2019, 1–16. [Google Scholar] [CrossRef] [Green Version]
  17. Sack, M.N.; Fyhrquist, F.Y.; Saijonmaa, O.J.; Fuster, V.; Kovacic, J.C. Basic Biology of Oxidative Stress and the Cardiovascular System. J. Am. Coll. Cardiol. 2017, 70, 196–211. [Google Scholar] [CrossRef]
  18. Grosso, G.; Godos, J.; Currenti, W.; Micek, A.; Falzone, L.; Libra, M.; Giampieri, F.; Forbes-Hernández, T.Y.; Quiles, J.L.; Battino, M.; et al. The Effect of Dietary Polyphenols on Vascular Health and Hypertension: Current Evidence and Mechanisms of Action. Nutrients 2022, 14, 545. [Google Scholar] [CrossRef]
  19. Ciumărnean, L.; Milaciu, M.V.; Runcan, O.; Vesa, S.C.; Răchișan, A.L.; Negrean, V.; Perné, M.-G.; Donca, V.I.; Alexescu, T.-G.; Para, I.; et al. The effects of favonoids in cardiovascular diseases. Molecules 2020, 25, 4320. [Google Scholar] [CrossRef]
  20. Keller, A.; Hull, S.E.; Elajaili, H.; Johnston, A.; Knaub, L.A.; Chun, J.H.; Walker, L.; Nozik-Grayck, E.; Reusch, J.E.B. (–)-Epicatechin Modulates Mitochondrial Redox in Vascular Cell Models of Oxidative Stress. Oxidative Med. Cell. Longev. 2020, 2020, 6392629. [Google Scholar] [CrossRef]
  21. Andriantsitohaina, R.; Auger, C.; Chataigneau, T.; Étienne-Selloum, N.; Li, H.; Martínez, M.C.; Schini-Kerth, V.B.; Laher, I. Molecular mechanisms of the cardiovascular protective effects of polyphenols. Br. J. Nutr. 2012, 108, 1532–1549. [Google Scholar] [CrossRef] [Green Version]
  22. Hurrell, R.; Egli, I. Iron bioavailability and dietary reference values. Am. J. Clin. Nutr. 2010, 91, 1461S–1467S. [Google Scholar] [CrossRef] [PubMed]
  23. Carlos, S.; De La Fuente-Arrillaga, C.; Bes-Rastrollo, M.; Razquin, C.; Rico-Campà, A.; Martínez-González, M.A.; Ruiz-Canela, M. Mediterranean Diet and Health Outcomes in the SUN Cohort. Nutrients 2018, 10, 439. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Willet, W. Nutritional Epidemiolgy; Oxford University Press: New York, NY, USA, 2012; Volume 40. [Google Scholar]
  25. De la Fuente-Arrillaga, C.; Vázquez-Ruiz, Z.; Bes-Rastrollo, M.; Sampson, L.; Martinez-Gonzalez, M.A. Reproducibility of an FFQ validated in Spain. Public Health Nutr. 2010, 13, 1364–1372. [Google Scholar] [CrossRef] [PubMed]
  26. Martin-Moreno, J.M.; Boyle, P.; Gorgojo, L.; Maisonneuve, P.; Fernandez-Rodriguez, J.C.; Salvini, S.; Willett, W.C. Development and Validation of a Food Frequency Questionnaire in Spain. Int. J. Epidemiol. 1993, 22, 512–519. [Google Scholar] [CrossRef] [PubMed]
  27. Moreiras, O.; Carbajar, A.; Cabrera, L.; Cuadrado, C. Tabla de Composición de Alimentos, 16th ed.; Piramide: Madrid, Spain, 2013. [Google Scholar]
  28. Mataix, J. Tabla de Composición de Alimentos, 5th ed.; Universidad de Granada: Granada, Spain, 2009. [Google Scholar]
  29. Neveu, V.; Pérez-Jiménez, J.; Vos, F.; Crespy, V.; du Chaffaut, L.; Mennen, L.; Knox, C.; Eisner, R.; Cruz, J.; Wishart, D.; et al. Phenol-Explorer: An online comprehensive database on polyphenol contents in foods. Database 2010, 2010, bap024. [Google Scholar] [CrossRef] [PubMed]
  30. Perezjimenez, J.; Neveu, V.; Vos, F.; Scalbert, A. Identification of the 100 richest dietary sources of polyphenols: An application of the Phenol-Explorer database. Eur. J. Clin. Nutr. 2010, 64, S112–S120. [Google Scholar] [CrossRef] [PubMed]
  31. Agencia Española de Seguridad Alimentaria y Nutrición (AESAN). Encuesta Nacional de Ingesta Dietética Española (National Dietary Intake Survey). Encuesta Nacional de Ingesta Dietética Española (National Dietary Intake Survey). Published 2011. Available online: https://docplayer.es/10558027-Enide-presentacion-n-de-enide-2011-encuesta-nacional-de-ingesta-dietetica-tica-espanola-aesan-aesan.html (accessed on 23 March 2022).
  32. Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Chaitman, B.R.; Bax, J.J.; Morrow, D.A.; White, H.D.; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). J. Am. Coll. Cardiol. 2018, 72, 2231–2264. [Google Scholar] [CrossRef]
  33. Bes-Rastrollo, M.; Valdivieso, J.R.P.; Sánchez-Villegas, A.; Alonso, Á.; Martínez-González, M.Á. Validation of self reported weight and body mass index in a cohort of university graduates in Spain. Rev. Esp. Obes. 2005, 3, 352–358. [Google Scholar]
  34. Martinez-Gonzalez, M.A.; López-Fontana, C.; Varo, J.J.; Sánchez-Villegas, A.; Martinez, J.A. Validation of the Spanish version of the physical activity questionnaire used in the Nurses’ Health Study and the Health Professionals’ Follow-up Study. Public Health Nutr. 2005, 8, 920–927. [Google Scholar] [CrossRef]
  35. Alonso, A.; Beunza, J.J.; Delgado-Rodríguez, M.; Martínez-González, M.A. Validation of self reported diagnosis of hypertension in a cohort of university graduates in Spain. BMC Public Health 2005, 5, 94. [Google Scholar] [CrossRef] [Green Version]
  36. Barrio-Lopez, M.T.; Bes-Rastrollo, M.; Beunza, J.J.; Fernandez-Montero, A.; Garcia-Lopez, M.; Martinez-Gonzalez, M.A. Validation of metabolic syndrome using medical records in the SUN cohort. BMC Public Health 2011, 11, 867. [Google Scholar] [CrossRef] [Green Version]
  37. Trichopoulou, A.; Costacou, T.; Bamia, C.; Trichopoulos, D. Adherence to a Mediterranean Diet and Survival in a Greek Population. N. Engl. J. Med. 2003, 348, 2599–2608. [Google Scholar] [CrossRef] [Green Version]
  38. Mendonça, R.D.; Carvalho, N.C.; Martin-Moreno, J.M.; Pimenta, A.M.; Lopes, A.C.S.; Gea, A.; Martinez-Gonzalez, M.A.; Bes-Rastrollo, M. Total polyphenol intake, polyphenol subtypes and incidence of cardiovascular disease: The SUN cohort study. Nutr. Metab. Cardiovasc. Dis. 2019, 29, 69–78. [Google Scholar] [CrossRef]
  39. Medina-Remón, A.; Estruch, R.; Tresserra-Rimbau, A.; Vallverdú-Queralt, A.; Lamuela-Raventos, R.M. The effect of polyphenol consumption on blood pressure. Mini-Rev. Med. Chem. 2013, 13, 1137–1149. [Google Scholar] [CrossRef]
  40. Tresserra-Rimbau, A.; Medina-Remón, A.; Pérez-Jiménez, J.; Martínez-González, M.A.; Covas, M.I.; Corella, D.; Salas-Salvadó, J.; Gómez-Gracia, E.; Lapetra, J.; Arós, F.; et al. Dietary intake and major food sources of polyphenols in a Spanish population at high cardiovascular risk: The PREDIMED study. Nutr. Metab. Cardiovasc. Dis. 2013, 23, 953–959. [Google Scholar] [CrossRef]
  41. Liu, X.; Qiu, J.; Zhao, S.; You, B.; Ji, X.; Wang, Y.; Cui, X.; Wang, Q.; Gao, H. Grape seed proanthocyanidin extract alleviates ouabain-induced vascular remodeling through regulation of endothelial function. Mol. Med. Rep. 2012, 6, 949–954. [Google Scholar] [CrossRef] [Green Version]
  42. Goetz, M.E.; Judd, S.E.; Safford, M.M.; Hartman, T.J.; McClellan, W.M.; Vaccarino, V. Dietary flavonoid intake and incident coronary heart disease: The REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Am. J. Clin. Nutr. 2016, 104, 1236–1244. [Google Scholar] [CrossRef] [Green Version]
  43. Simons, A.L.; Renouf, M.; Hendrich, S.; Murphy, P.A. Human Gut Microbial Degradation of Flavonoids: Structure-Function Relationships. J. Agric. Food Chem. 2005, 53, 4258–4263. [Google Scholar] [CrossRef] [Green Version]
  44. Cassidy, A.; Mukamal, K.J.; Liu, L.; Franz, M.; Eliassen, A.H.; Rimm, E.B. High Anthocyanin Intake Is Associated with a Reduced Risk of Myocardial Infarction in Young and Middle-Aged Women. Circulation 2013, 127, 188–196. [Google Scholar] [CrossRef] [Green Version]
  45. Micek, A.; Godos, J.; Del Rio, D.; Galvano, F.; Grosso, G. Dietary Flavonoids and Cardiovascular Disease: A Comprehensive Dose-Response Meta-Analysis. Mol. Nutr. Food Res. 2021, 65, 2001019. [Google Scholar] [CrossRef]
  46. Wang, X.; Ouyang, Y.Y.; Liu, J.; Zhao, G. Flavonoid intake and risk of CVD: A systematic review and meta-analysis of prospective cohort studies. Br. J. Nutr. 2014, 111, 1–11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Mursu, J.; Voutilainen, S.; Nurmi, T.; Tuomainen, T.-P.; Kurl, S.; Salonen, J.T. Flavonoid intake and the risk of ischaemic stroke and CVD mortality in middle-aged Finnish men: The Kuopio Ischaemic Heart Disease Risk Factor Study. Br. J. Nutr. 2008, 100, 890–895. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Adriouch, S.; Lampuré, A.; Nechba, A.; Baudry, J.; Assmann, K.; Kesse-Guyot, E.; Hercberg, S.; Scalbert, A.; Touvier, M.; Fezeu, L.K. Prospective Association between Total and Specific Dietary Polyphenol Intakes and Cardiovascular Disease Risk in the Nutrinet-Santé French Cohort. Nutrients 2018, 10, 1587. [Google Scholar] [CrossRef] [Green Version]
  49. Dower, J.I.; Geleijnse, J.M.; Gijsbers, L.; Zock, P.; Kromhout, D.; Hollman, P.C.H. Effects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health: A randomized, double-blind, placebo-controlled, crossover trial. Am. J. Clin. Nutr. 2015, 101, 914–921. [Google Scholar] [CrossRef] [PubMed]
  50. Leyva-Soto, A.; Chavez-Santoscoy, R.A.; Porras, O.; Hidalgo-Ledesma, M.; Serrano-Medina, A.; Ramírez-Rodríguez, A.A.; Castillo-Martinez, N.A. Epicatechin and quercetin exhibit in vitro antioxidant effect, improve biochemical parameters related to metabolic syndrome, and decrease cellular genotoxicity in humans. Food Res. Int. 2021, 142, 110101. [Google Scholar] [CrossRef] [PubMed]
  51. Hu, Y.; Li, Y.; Sampson, L.; Wang, M.; Manson, J.E.; Rimm, E.; Sun, Q. Lignan Intake and Risk of Coronary Heart Disease. J. Am. Coll. Cardiol. 2021, 78, 666–678. [Google Scholar] [CrossRef] [PubMed]
  52. Miller, A.P.; Coronel, J.; Amengual, J. The role of β-carotene and vitamin A in atherogenesis: Evidences from preclinical and clinical studies. Biochim. Biophys. Acta (BBA)-Mol. Cell Biol. Lipids 2020, 1865, 158635. [Google Scholar] [CrossRef] [PubMed]
  53. Zhou, F.; Wu, X.; Pinos, I.; Abraham, B.M.; Barrett, T.J.; von Lintig, J.; Fisher, E.A.; Amengual, J. β-Carotene conversion to vitamin A delays atherosclerosis progression by decreasing hepatic lipid secretion in mice. J. Lipid Res. 2020, 61, 1491–1503. [Google Scholar] [CrossRef]
  54. Amengual, J.; Coronel, J.; Marques, C.; Aradillas-García, C.; Morales, J.M.V.; Andrade, F.C.D.; Erdman, J.W.; Teran-Garcia, M. β-Carotene Oxygenase 1 Activity Modulates Circulating Cholesterol Concentrations in Mice and Humans. J. Nutr. 2020, 150, 2023–2030. [Google Scholar] [CrossRef]
  55. Guasch-Ferré, M.; Li, Y.; Willett, W.C.; Sun, Q.; Sampson, L.; Salas-Salvadó, J.; Martínez-González, M.A.; Stampfer, M.J.; Hu, F.B. Consumption of Olive Oil and Risk of Total and Cause-Specific Mortality among U.S. Adults. J. Am. Coll. Cardiol. 2022, 79, 101–112. [Google Scholar] [CrossRef]
  56. Guasch-Ferré, M.; Liu, G.; Li, Y.; Sampson, L.; Manson, J.E.; Salas-Salvadó, J.; Martínez-González, M.A.; Stampfer, M.J.; Willett, W.C.; Sun, Q.; et al. Olive Oil Consumption and Cardiovascular Risk in U.S. Adults. J. Am. Coll. Cardiol. 2020, 75, 1729–1739. [Google Scholar] [CrossRef]
  57. Zong, G.; Li, Y.; Sampson, L.; Dougherty, L.W.; Willett, W.C.; Wanders, A.J.; Alssema, M.; Zock, P.; Hu, F.B.; Sun, Q. Monounsaturated fats from plant and animal sources in relation to risk of coronary heart disease among US men and women. Am. J. Clin. Nutr. 2018, 107, 445–453. [Google Scholar] [CrossRef]
  58. Fuentes, E.; Palomo, I. Mechanisms of endothelial cell protection by hydroxycinnamic acids. Vasc. Pharmacol. 2014, 63, 155–161. [Google Scholar] [CrossRef]
  59. Coman, V.; Vodnar, D.C. Hydroxycinnamic acids and human health: Recent advances. J. Sci. Food Agric. 2020, 100, 483–499. [Google Scholar] [CrossRef]
  60. Macarro, M.S.; Rodríguez, J.P.M.; Morell, E.B.; Pérez-Piñero, S.; Victoria-Montesinos, D.; García-Muñoz, A.M.; García, F.C.; Sánchez, J.C.; López-Román, F.J. Effect of a Combination of Citrus Flavones and Flavanones and Olive Polyphenols for the Reduction of Cardiovascular Disease Risk: An Exploratory Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects. Nutrients 2020, 12, 1475. [Google Scholar] [CrossRef]
  61. Martínez-Maqueda, D.; Zapatera, B.; Gallego-Narbón, A.; Vaquero, M.P.; Saura-Calixto, F.; Pérez-Jiménez, J. A 6-week supplementation with grape pomace to subjects at cardiometabolic risk ameliorates insulin sensitivity, without affecting other metabolic syndrome markers. Food Funct. 2018, 9, 6010–6019. [Google Scholar] [CrossRef]
  62. Pedret, A.; Fernández-Castillejo, S.; Valls, R.-M.; Catalán, U.; Rubió, L.; Romeu, M.; Macià, A.; Hazas, M.C.L.D.L.; Farràs, M.; Giralt, M.; et al. Cardiovascular Benefits of Phenol-Enriched Virgin Olive Oils: New Insights from the Virgin Olive Oil and HDL Functionality (VOHF) Study. Mol. Nutr. Food Res. 2018, 62, e1800456. [Google Scholar] [CrossRef]
  63. Kirch, N.; Berk, L.; Liegl, Y.; Adelsbach, M.; Zimmermann, B.F.; Stehle, P.; Stoffel-Wagner, B.; Ludwig, N.; Schieber, A.; Helfrich, H.-P.; et al. A nutritive dose of pure (–)-epicatechin does not beneficially affect increased cardiometabolic risk factors in overweight-to-obese adults—A randomized, placebo-controlled, double-blind crossover study. Am. J. Clin. Nutr. 2018, 107, 948–956. [Google Scholar] [CrossRef]
  64. Burkholder-Cooley, N.M.; Rajaram, S.S.; Haddad, E.H.; Oda, K.; Fraser, G.E.; Jaceldo-Siegl, K. Validating polyphenol intake estimates from a food-frequency questionnaire by using repeated 24-h dietary recalls and a unique method-of-triads approach with 2 biomarkers. Am. J. Clin. Nutr. 2017, 105, 685–694. [Google Scholar] [CrossRef] [Green Version]
Antioxidants 11 00783 g001 550
Figure 1. Flowchart of participants in the SUN (‘Seguimiento Universidad de Navarra’) included in analyses of (poly)phenol intake and incident cardiovascular diseases. Abbreviation: Food frequency questionnaire (FFQ).
Figure 1. Flowchart of participants in the SUN (‘Seguimiento Universidad de Navarra’) included in analyses of (poly)phenol intake and incident cardiovascular diseases. Abbreviation: Food frequency questionnaire (FFQ).
Antioxidants 11 00783 g001
Antioxidants 11 00783 g002 550
Figure 2. Nelson–Aalen cumulative hazard ratios estimates of cardiovascular disease according to low intake (Q1) vs. a medium-high (Q2–Q5) total PI. Multivariable adjusted model 1 using inverse probability weighting to adjust for sex, age, energy intake (kcal/day), smoking status (never smoker, current smoker or former smoker), lifetime tobacco exposure (packs-years), BMI (kg/m2) and the quadratic term, dyslipidemia(yes/no), hypertension(yes/no), diabetes, family history of CVD (yes/no), physical activity (metabolic equivalents-h/week), TV watching (hours/day), use of cardiovascular drugs (yes/no), health consciousness (quintiles), energy-adjusted alcohol intake (g/day), and energy-adjusted sodium intake (g/day).
Figure 2. Nelson–Aalen cumulative hazard ratios estimates of cardiovascular disease according to low intake (Q1) vs. a medium-high (Q2–Q5) total PI. Multivariable adjusted model 1 using inverse probability weighting to adjust for sex, age, energy intake (kcal/day), smoking status (never smoker, current smoker or former smoker), lifetime tobacco exposure (packs-years), BMI (kg/m2) and the quadratic term, dyslipidemia(yes/no), hypertension(yes/no), diabetes, family history of CVD (yes/no), physical activity (metabolic equivalents-h/week), TV watching (hours/day), use of cardiovascular drugs (yes/no), health consciousness (quintiles), energy-adjusted alcohol intake (g/day), and energy-adjusted sodium intake (g/day).
Antioxidants 11 00783 g002
Table
Table 1. Baseline characteristics * of participants across sex-specific energy-adjusted quintiles of total (poly)phenol dietary intake.
Table 1. Baseline characteristics * of participants across sex-specific energy-adjusted quintiles of total (poly)phenol dietary intake.
Energy-Adjusted Quintiles of Total (Poly)Phenol Intake
Q1
(n = 3230)		Q2
(n = 3229)		Q3
(n = 3230)		Q4
(n = 3229)		Q5
(n = 3229)
Age (years)38.5 (13.5)37.3 (12.0)37.1 (11.5)37.2 (11.2)37.2 (11.6)
Sex (% female)61.0%61.1%61.3%61.4%62.2%
Total (poly)phenol intake (mg/day)375.7 (90.7)547.1 (36.5)667.36 (35.6)806.4 (49.1)1149 (304.4)
Flavonoids intake (mg/day)202.9 (85.7)313.1 (78.4)394.4 (91.5)495.4 (116.4)768.9 (312.6)
Phenol acids intake (mg/day)180.7 (70.0)250.0 (74.5)294.0 (85.8)343.9 (107.2)441.8 (180.3)
Lignans intake (mg/day)1.6 (0.6)1.9 (0.6)2.2 (0.7)2.4 (0.8)2.9 (1.3)
Stilbenes intake (mg/day)0.6 (1.1)0.9 (1.6)1.2 (2.1)1.4 (2.6)1.8 (3.7)
Other (poly)phenols intake (mg/day) 27.1 (19.2)34.2 (19.6)39.9 (22.2)45.1 (27.5)55.1 (50.6)
Body mass Index (kg/m2)23.5 (3.6)23.5 (3.5)23.5 (3.5)23.5 (3.5)23.3 (3.6)
Physical activity (METs-h/week)18.7 (21.5)19.6 (20.3)21.7 (22.2)23.5 (23.4)26.5 (27.8)
Marital status (% married)37.9%45.2%51.9%54.5%57.9%
University education (years)5.0 (1.4)5.1 (1.5)5.1 (1.5)5.1 (1.5)5.0 (1.5)
TV watching time (hours)1.7 (1.3)1.6 (1.2)1.6 (1.2)1.6 (1.2)1.6 (1.2)
Smoking
 Current smoker22.2%22.0%20.9%22.4%21.5%
 Former smoker26.0%26.9%29.7%28.8%29.6%
 Never smoker51.1%50.4%48.8%48.1%48.3%
Package-years of smoking5.2 (11.1)4.4 (9.2)4.4 (8.9)4.5 (8.7)4.8 (9.3)
Dyslipidemia at baseline15.1%15.1%16.8%17.9%17.8%
Hypertension at baseline10.6%10.2%9.7%9.2%9.4%
Family history of CVD 7.7%8.2%7.1%7.4%8.2%
Diabetes at baseline2.4%1.1%1.5%2.1%1.6%
Use of cardiovascular drugs 2.9%2.6%2.5%2.3%2.6%
Total energy intake (kcal/day)2580 (563)2310 (585)2258 (595)2305 (588)2480 (609)
Carbohydrate intake (% energy)42.4 (7.3)42.2 (6.7)42.8 (6.6)43.9 (6.6)46.0 (7.4)
Protein intake (% energy)17.9 (3.2)18.4 (3.0)18.5 (3.0)18.4 (3.2)17.6 (3.0)
Fat intake (% energy)38.2 (6.4)37.6 (5.9)36.7 (5.8)35.6 (5.9)34.2 (6.5)
Dietary fiber intake (g/day)23.7 (8.8)24.3 (9.0)26.5 (9.4)29.5 (10.6)36.6 (15.2)
Alcohol intake (g/day)5.5 (9.8)5.9 (8.4)6.3 (8.8)7.0 (9.8)7.5 (11.4)
Adherence to MDS (0–9 score)3.5 (1.6)3.9 (1.6)4.3 (1.7)4.8 (1.7)5.2 (1.7)
Abbreviatures: Q, Quintile; MET metabolic equivalents; SUN, Seguimiento Universidad de Navarra; CVD Cardiovascular disease; MDS, Mediterranean Diet Score proposed by Trichopoulou et al. [37]. * Adjusted for inverse probability weighting for sex and age. Values are expressed as means and standard deviations or percentages.
Table
Table 2. Contribution of (poly)phenol subclasses to total (poly)phenol intake and dietary sources.
Table 2. Contribution of (poly)phenol subclasses to total (poly)phenol intake and dietary sources.
(Poly)phenol Classes and SubclassesMean (mg/d) ± SD, (%)Food Sources * (% of Contribution)
Flavonoids432.9 ± 271.6, (55.5)
 Anthocyanins37.9 ± 43.3, (4.8)Cherries (45.6), strawberries (16), red wine (13.7), grapes (13.6), olives (8), beans (1.2) milkshakes (1.1).
 Chalcones0.031 ± 0.006, (< 0.1)Beer (100).
 Dihydrochalcones1.9 ± 2.6, (0.2)Apples (100).
 Dihydroflavonols1.4 ± 3.2, (0.2)Red wine (98.3), other wines (1.8).
 Flavan-3-ols21.1 ± 16, (2.7)Apples (26.9), chocolate (9.9), red wine (14.6), peaches (10.2), cherries (6.7), grapes (5.7), strawberries (3), green beans (2.5), banana (2.5) lentils (1.26).
 Flavanones74.6 ± 75.8, (9.6)Oranges (33.7), natural orange juice (27.5), fruit juices from concentrate (18.7), other fruit juices (1.5), tomato (1.14).
 Flavones17.6 ± 13.4, (2.2)Other vegetables (36.5), natural orange juice (17.3), cookies (11), olives (6), fruit juices from concentrate (4.4), chocolate cookies (3.3), watermelon (2.9), industrial bakery (2.3) pastries (2.2), croquettes (1.8), peppers (1.8), pizza (1.4), cupcake (1.1) carrots and pumpkin (1).
 Flavonols57.1 ± 35.8, (7.3)Lettuce (36.5), swiss chard leaves (29.2), asparagus (7), olives (2), nuts (3.2), green beans (2.8), chocolate (1.7), cabbage (1.7), tomato (1.6), apples (1.5).
 Isoflavonoids0.03 ± 0.03, (< 0.1)Beans (67.9), nuts (29.5), beer (2.5).
 Proanthocyanidins221.3 ± 198.2, (28.4)Chocolate (44.4), apple (21), cherries (11.1), strawberries (5.34), grapes (4.7), nuts (4.5), red wine (3.1), beans (3).
Lignans2.2 ± 1.1, (0.3)Carrot and pumpkin (13.3), olive oil (11.2), tomato (9), broccoli and cabbage (7.6), oranges (6.8), green beans (6), peaches (4.4), pepper (3.5), strawberries (3.2), cookies (3) asparagus (2.8), gazpacho (2.8), red wine (2.7), apples (2.3), grapes (1.9), eggplant zucchini and cucumber (1.7), dried fruit (1.6), kiwi (1.4), fried potatoes (1.3), melon (1.3), nuts (1.24) bread (1.1).
Phenolic acids302.9 ± 151.9, (38.8)
 Hydroxybenzoic acids31.6 ± 24.8, (4.1)Nuts (34.4), olives (16.4), strawberries (13), carrots and pumpkin (11.9), swiss chard leaves (7.4), red wine (5.2), beer (2.4), apples (1.4), banana (1).
 Hydroxycinnamic acids266.3 ± 140.1, (34.2)Coffee (31.9), decaffeinated coffee (12.7), other vegetable (8.5) carrots and pumpkin (7.8) cherries (7), French fries (5.7), olives (4.9), apple (4.3), baked or boiled potatoes (3) tomato (1.85) nuts (1.6), peaches (1.5) orange juice (1.3) red wine (1.2).
 Hydroxyphenylpropanoic acids0.6 ± 1, (< 0.1)Olives (100).
 Hydroxyphenylacetic acids4.44 ± 6.9, (0.6)Olives (96.6), red wine (2.5).
Stilbenes1.21 ± 2.6, (0.2)Red wine (88.6), grapes (4), other wines (3.6), strawberries (2.5).
Other (poly)phenols40.5 ± 33.14, (5.2)
 Alkylmethoxyphenols0.3 ± 0.6, (0.3)Decaffeinated coffee (84.6) beer (15.3).
 Alkylphenols8.1 ±11.2, (1)Breakfast cereals (43.2), whole-grain bread (41.7), pasta (8), cookies (2.5).
 Furanocoumarins0.4 ± 0.8, (0.4)Other vegetables (100).
 Hydroxybenzaldehydes0.2 ± 0.4, (0.2)Red wine (90.7), beer (2.7), other wines (2.7), olives (2), whisky (1.4).
 Hydroxybenzoketones0.001 ± 0.002, (< 0.1)Beer (100)
 Hydroxycoumarins0.04 ± 0.08, (< 0.1)Beer (75), other wines (24.9)
 Methoxyphenols0.03 ± 0.07, (< 0.1)Decaffeinated coffee (100)
 Tyrosols27.2 ± 29.9, (3.5)Olives (66.1), olive oil (28.9), red wine (0.9)
 Other (poly)phenols (subclass)4.5 ± 6.4, (0.6)Orange juice (65.2), other fruits juice (24.4), Coffee (5.61), apples (256), olives (1.5)
* Food sources that contribute more than 1%.
Table
Table 3. Hazard ratio (HR) and 95% confidence intervals (CI) of confirmed cardiovascular disease cases according to quintiles of total (poly)phenol intake and (poly)phenol subclasses.
Table 3. Hazard ratio (HR) and 95% confidence intervals (CI) of confirmed cardiovascular disease cases according to quintiles of total (poly)phenol intake and (poly)phenol subclasses.
Energy-Adjusted Quintiles of Total (Poly)Phenol Intake Low Intake vs. Medium–High Intake
12345p For Trend
n = 3230n = 3229n = 3230n = 3229n = 3229Q1 vs. Q2–Q5
Total (poly)phenol intake
Median intake (mg/d)432.1600.4729.7883.41171.1
Cases2716182636
Person-years3703837880376103665736468
Age-sex adjusted HR (95% CI)1 (ref.)0.42 (0.22–0.78) **0.43 (0.24–0.79) **0.52 (0.30–0.9) *0.56 (0.33–0.93) *0.292.04 (1.32–3.15) **
Multivariable adjusted model 11 (ref.)0.33 (0.15–0.71) **0.47 (0.23–0.95) *0.55 (0.29–1.05)0.52 (0.28–0.96) *0.292.12 (1.27–3.57) **
 Model 1 restricted to >40 years1 (ref.)0.55 (0.27–1.14)0.66 (0.33–1.32)0.64 (0.33–1.24)0.66 (0.35–1.24)0.341.58 (0.94–2.64)
Repeated Measurements adjusted model 11 (ref.)0.39 (0.18–0.89) *0.57 (0.28–1.14)0.63 (0.33–1.21)0.56 (0.30–1.05)0.301.85 (1.09–3.16) *
 Model 1 restricted to >40 years1 (ref.)0.56 (0.27–1.16)0.67 (0.34–1.31)0.68 (0.34–1.20)0.64 (0.34–1.20)0.351.56 (0.93–2.60)
Flavonoids intake
Median intake (mg/d)190.7300.3385.7496.2720.4
Cases2713292430
Person-years3770137642374493661836243
Age-sex adjusted HR (95% CI)1 (ref.)0.35 (0.18–0.69) **0.70 (0.41–1.19)0.54 (0.31–0.94) *0.54 (0.32–0.92) *0.191.86 (1.20–2.87) **
Multivariable adjusted model 11 (ref.)0.32 (0.14–0.71) **1.01 (0.54–1.89)0.59 (0.31–1.15)0.51 (0.26–1.00) *0.131.73 (1.03–2.90) *
 Model 1 restricted to >40 years1 (ref.)0.27 (0.12–0.63) **1.11 (0.60–2.04)0.52 (0.26–1.03)0.48 (0.24–0.94) *0.102.27 (1.33–3.88) **
Repeated Measurements adjusted model 11 (ref.)0.27 (0.11–0.63) **0.88 (0.47–1.65)0.64 (0.33–1.22)0.44 (0.22–0.88) *0.081.88 (1.11–3.17) *
 Model 1 restricted to >40 years1 (ref.)0.28 (0.14–0.64) **0.85 (0.46–1.58)0.51 (0.26–1.00)0.44 (0.22–0.87) *0.061.97 (1.19–3.27) **
Lignans intake
Median intake (mg/d)1.21.72.12.53.3
Cases2632212326
Person-years3869238276373723627935034
Age-sex adjusted HR (95% CI)1 (ref.)1.10 (0.63–1.92)0.73 (0.40–1.35)0.66 (0.36–1.21)0.61 (0.33–1.11)0.031.29 (0.78–2.09)
Multivariable adjusted model 11 (ref.)1.12 (0.60–2.09)0.72 (0.35–1.45)0.75 (0.37–1.52)0.51 (0.25–1.04)0.021.26 (0.73–2.19)
 Model 1 restricted to >40 years1 (ref.)0.95 (0.51–1.78)0.79 (0.38–1.50)0.65 (0.32–1.31)0.42 (0.20–0.87) *<0.011.83 (1.03–3.25) *
Repeated Measurements adjusted model 11 (ref.)1.41 (0.74–2.68)0.80 (0.39–1.64)0.87 (0.42–1.82)0.61 (0.30–1.29)0.041.06 (0.59–1.90)
 Model 1 restricted to >40 years1 (ref.)1.40 (0.74–2.60)0.87 (0.43–1.73)0.72 (0.33–1.53)0.58 (0.28–1.24)0.031.08 (0.62–1.89)
Phenolic acids intake
Median intake (mg/d)146.3220.7285.1351.2480.3
Cases2027192235
Person-years3695936959370683768237486
Age-sex adjusted HR (95% CI)1 (ref.)0.82 (0.46–1.47)0.54 (0.29–1.02)0.62 (0.33–1.15)0.78 (0.44–1.37)0.551.44 (0.89–2.35)
Multivariable adjusted model 11 (ref.)0.70 (0.35–1.40)0.35 (0.16–0.80) *0.57 (0.28–1.15)0.67 (0.34–1.29)0.481.74 (0.99–3.09)
 Model 1 restricted to >40 years1 (ref.)0.74 (0.38–1.43) *0.39 (0.20–0.86) *0.62 (0.31–1.24)0.78 (0.42–1.44)0.531.97 (1.12–3.45) *
Repeated Measurements adjusted model 11 (ref.)0.92 (0.46–1.82)0.44 (0.20–0.95) *0.60 (0.29–1.25)0.77 (0.39–1.52)0.501.47 (0.82–2.62)
 Model 1 restricted to >40 years1 (ref.)0.62 (0.32–1.23)0.43 (0.20–0.91) *0.60 (0.30–1.19)0.71 (0.4–1.33)0.571.66 (0.98–2.80)
Stilbenes intake
Median intake (mg/d)−0.010.10.40.83.5
Cases1610232252
Person-years3762936446362903696138328
Age-sex adjusted HR (95% CI)1 (ref.)0.61 (0.27–1.34)1.05 (0.55–1.99)0.8(0 0.42–1.54)1.26(0.71–2.24)0.051.01 (0.60–1.72)
Multivariable adjusted model 11 (ref.)0.55 (0.22–1.38)1.21 (0.55–2.64)0.80 (0.36–1.75)1.1(0.52–2.27)0.441.11 (0.58–2.10)
 Model 1 restricted to >40 years1 (ref.)0.72 (0.32–1.60)0.82 (0.36–1.88)0.91 (0.43–1.93)1.05(0.51–2.19)0.520.94 (0.46–1.90)
Repeated Measurements adjusted model 11 (ref.)0.48 (0.19–1.19)0.96 (0.44–2.10)0.76 (0.35–1.63)0.97 (0.47–2.00)0.431.26(0.66–2.36)
 Model 1 restricted to >40 years1 (ref.)0.94 (0.44–2.00)0.55 (0.22–1.34)0.82 (0.39–1.75)1.12(0.54–2.32)0.601.13(0.6–2.11)
Other (poly)phenols intake
Median intake (mg/d)14.225.434.045.272.1
Cases3021222129
Person-years3833237833369383615536396
Age-sex adjusted HR (95% CI)1(ref.)0.70 (0.40–1.23)0.80 (0.45–1.38)0.74 (0.42–1.39)0.79 (0.47–1.32)0.571.32 (0.87–2.00)
Multivariable adjusted model 11(ref.)0.87 (0.45–1.70)0.89 (0.45–1.76)0.76 (0.38–1.51)0.95 (0.51–1.79)0.921.15 (0.68–1.93)
 Model 1 restricted to >40 years1(ref.)0.81 (0.41–1.59) 0.81 (0.40–1.62)0.74 (0.37–1.50)0.98 (0.52–1.87)0.941.18 (0.66–2.08)
Repeated Measurements adjusted model 11(ref.)0.74 (0.38–1.45) 0.77 (0.39–1.50)0.79 (0.40–1.55)0.91 (0.50–1.70)0.971.23 (0.74–2.05)
 Model 1 restricted to >40 years1(ref.)0.84 (0.42–1.62)0.62 (0.31–1.26)0.87 (0.45–1.75)0.96 (0.51–1.82)0.811.21 (0.72–2.02)
* p < 0.05, ** p < 0.01. Abbreviatures: CI, confidence interval; HR, hazard ratio; Q, quintile; ref., reference. All Cox regression models used age as the underlying time variable and were also stratified by age (five-year periods), recruitment period, marital status, and years of university education. Multivariable adjusted model 1: Additionally adjusted for energy intake (kcal/day), smoking status (never smoker, current smoker or former smoker), lifetime tobacco exposure (packs-years), BMI (kg/m2) and the quadratic term, dyslipidemia, hypertension (yes/no), diabetes(yes/no), family history of cardiovascular disease (yes/no), physical activity (metabolic equivalents-h/week), TV watching (hours/day), use of cardiovascular drugs (yes/no), health consciousness (quintiles), energy-adjusted alcohol intake (g/day) and energy-adjusted sodium intake (g/day). Repeated measurements model 1 were adjusted by the same variables on model 1 with updated data at 10 years of follow-up (except physical activity, TV watching, and health consciousness) using cumulative average for dietary variables.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Vázquez-Ruiz, Z.; Toledo, E.; Vitelli-Storelli, F.; Goni, L.; de la O, V.; Bes-Rastrollo, M.; Martínez-González, M.Á. Effect of Dietary Phenolic Compounds on Incidence of Cardiovascular Disease in the SUN Project; 10 Years of Follow-Up. Antioxidants 2022, 11, 783. https://doi.org/10.3390/antiox11040783

AMA Style

Vázquez-Ruiz Z, Toledo E, Vitelli-Storelli F, Goni L, de la O V, Bes-Rastrollo M, Martínez-González MÁ. Effect of Dietary Phenolic Compounds on Incidence of Cardiovascular Disease in the SUN Project; 10 Years of Follow-Up. Antioxidants. 2022; 11(4):783. https://doi.org/10.3390/antiox11040783

Chicago/Turabian Style

Vázquez-Ruiz, Zenaida, Estefanía Toledo, Facundo Vitelli-Storelli, Leticia Goni, Víctor de la O, Maira Bes-Rastrollo, and Miguel Ángel Martínez-González. 2022. "Effect of Dietary Phenolic Compounds on Incidence of Cardiovascular Disease in the SUN Project; 10 Years of Follow-Up" Antioxidants 11, no. 4: 783. https://doi.org/10.3390/antiox11040783

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop